The Yale Diabetes Research Center (DRC) was established in 1993 with the goal of promoting research in diabetes and related metabolic and endocrine disorders at the University. The DRC brings together a multidisciplinary group of over 100 member and associate member scientists as well as professional supporting staff, new investigators and research trainees from in many departments and 4 colleges or schools at Yale University The scope of the research activities of the membership is very broad, ranging from basic molecular and cellular biology to whole body physiology and the treatment of diabetic patients. DRC members, however, share a common interest in research focused on diabetes or related metabolic disorders or that is fundamental to the understanding of its pathogenesis or for the development of new diabetes treatment strategies. The design of the Yale DRC is aimed at developing an infrastructure that could serve as a catalyst to achieve these goals. The cornerstone of the DRC is its five Research Cores that provide funded basic and clinical investigators with the opportunity to more efficiently utilize resources and expand the scope of their research programs. The Clinical Metabolism and the Diabetes Translational Cores facilitate metabolic research in patients, whereas the Molecular Genetic Mouse Core, Physiology and Cell Biology Cores that comprise the more basic science focus of the Center offer investigators the tools to create and test novel animal models starting from the molecule and ending with biological outcomes. The Administrative Core oversees the operation of the Center, its Pilot/Feasibility Project and Enrichment Programs, and helps to coordinate patient-based research in diabetes. The goals of the DRC are to: 1) stimulate multidisciplinary interactions, particularly between basic and clinical scientists; 2) encourage established investigators not presently working in diabetes-related areas, to bring their expertise to bear on problems relevant to diabetes; 3) efficiently organize tim e consuming and/or costly techniques through Core facilities to enhance the productivity of investigators conducting research in diabetes related areas; 4) promote new research programs through pilot feasibility projects; 5) enhance the quality of diabetes research training, and 6) create a stimulating institutional environment that expands research efforts of its members to achieve new strategies to prevent and treat diabetes at the local, and ultimately at the national level.

Public Health Relevance

The Yale Diabetes Research Center provides the scientific infrastructure to support a wide spectrum of clinical and basic scientists who are working to better understand the factors driving the development of diabetes and to facilitate the translation of discoveries from the bench to the bedside that lead to new strategies for the treatment of individuals with, or who are at risk for developing diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK045735-29
Application #
10104473
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Silva, Corinne M
Project Start
1997-01-01
Project End
2023-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
29
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Hwang, Janice Jin; Parikh, Lisa; Lacadie, Cheryl et al. (2018) Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia. J Clin Invest 128:1485-1495
Wang, Yongliang; Nasiri, Ali R; Damsky, William E et al. (2018) Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. Cell Rep 24:47-55
RISE Consortium (2018) Impact of Insulin and Metformin Versus Metformin Alone on ?-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care 41:1717-1725
Tan, Qiyuan; Tai, Ningwen; Li, Yangyang et al. (2018) Activation-induced cytidine deaminase deficiency accelerates autoimmune diabetes in NOD mice. JCI Insight 3:
Madiraju, Anila K; Qiu, Yang; Perry, Rachel J et al. (2018) Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med 24:1384-1394
Goldberg, Ira J; Reue, Karen; Abumrad, Nada A et al. (2018) Deciphering the Role of Lipid Droplets in Cardiovascular Disease: A Report From the 2017 National Heart, Lung, and Blood Institute Workshop. Circulation 138:305-315
Stamatouli, Angeliki M; Quandt, Zoe; Perdigoto, Ana Luisa et al. (2018) Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 67:1471-1480
Li, Nina Xiaoyan; Brown, Stacey; Kowalski, Tim et al. (2018) GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia. Diabetes 67:1401-1413
Qiu, Yang; Perry, Rachel J; Camporez, João-Paulo G et al. (2018) In vivo studies on the mechanism of methylene cyclopropyl acetic acid and methylene cyclopropyl glycine-induced hypoglycemia. Biochem J 475:1063-1074
Perry, Rachel J; Peng, Liang; Cline, Gary W et al. (2018) Publisher Correction: Non-invasive assessment of hepatic mitochondrial metabolism by positional isotopomer NMR tracer analysis (PINTA). Nat Commun 9:498

Showing the most recent 10 out of 620 publications